or
forgot password

Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer


Phase 2
18 Years
N/A
Open (Enrolling)
Female
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer

Thank you

Trial Information

Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer


PRIMARY OBJECTIVES:

I. To evaluate the efficacy of single agent ABT-888 (veliparib) (NSC 737664) in BRCA
carriers with metastatic breast cancer based on response rate (RECIST criteria).

SECONDARY OBJECTIVES:

I. To conduct subset analysis on BRCA1 vs. BRCA2 and hormone receptor status. II. To
evaluate progression-free survival of patients on single-agent ABT-888. III. To further
describe the safety and tolerability of ABT-888 (NSC 737664) as a single agent and in
combination with carboplatin for BRCA-associated breast cancer.

IV. To evaluate the pharmacokinetics of ABT-888 (NSC 737664) alone and in combination with
carboplatin.

V. To assess the relationship between the level of PARP inhibition by ABT-888 and biomarkers
of DNA damage in PBMC's and in tumor VI. To explore the relationship between biomarkers of
drug effect and progression-free survival.

VII. To evaluate the efficacy and safety of the combination of carboplatin and ABT-888 in
patients who have failed single agent ABT-888.

VIII. To conduct subset analysis on BRCA1 vs. BRCA2 and hormone receptor status.

OUTLINE: This is a multicenter study. Patients are stratified according to ECOG performance
status (0-1 vs 2), and hormone status (estrogen receptor [ER]- and/or progesterone receptor
[PR]-positive vs ER- and/or PR-negative). Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive oral veliparib twice daily on days 1-21.

ARM II: Patients receive carboplatin IV over 30 minutes on day 1 and veliparib as in arm I.

In both arms, treatment repeats every 21 days in the absence of disease progression or
unacceptable toxicity. Patients undergo blood and hair follicle sample collection for
pharmacokinetics and other laboratory studies.

After completion of study therapy, patients are followed up every 3-6 months.


Inclusion Criteria:



- Histologically confirmed breast cancer

- Metastatic or locally advanced disease

- Disease not amenable to surgery

- Standard curative measures do not exist or are no longer effective

- Patient must have a known deleterious BRCA mutation confirmed by report from a CLIA
certified laboratory

- Measurable disease by RECIST criteria

- At least 3 weeks since prior chemotherapy

- Hormone receptor status known

- ECOG performance status 0-2

- Life expectancy > 4 months

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN if there is evidence of liver metastasis)

- Creatinine normal OR creatinine clearance ≥ 60 mL/min

- Negative pregnancy test

- Fertile patients must agree to use effective contraception before, during, and for 3
months after completion of study therapy

- Ability to understand and the willingness to sign a written informed consent document

- No prior therapy with platinum agents or PARP inhibitors

- Prior adjuvant platinum agents within the past 12 months allowed

- No other concurrent investigational agents

- No known CNS metastases with active symptomatology, or requiring anticonvulsant
medications or steroids

- Patients on anticonvulsant medications prescribed for reasons other than CNS
metastases, not on steroids and without active symptomatology allowed

- Patients with active seizure or a history of seizure; patients with CNS metastases
must be stable after therapy for > 3 months and off steroid treatment prior to study
enrollment

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to veliparib or PARP Inhibitors

- No contraindications to platinum agents

- More than 5 years since prior and no concurrent non-breast malignancy except
nonmelanoma skin cancer or resected stage I ovarian cancer

- No intercurrent illness (e.g., cardiovascular, pulmonary, or central nervous system)
that is either poorly controlled with currently available treatment or that, in the
opinion of the investigator, is deemed unwise to enter the patient on the protocol

- Not pregnant or nursing

- Patients unable to swallow the ABT-888 tablets whole are ineligible; (the tablets
cannot be crushed or broken)

- No active severe infection, including known infection with HIV or hepatitis B or C
virus

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate as measured by RECIST version 1.1

Outcome Time Frame:

Up to 4 years

Safety Issue:

No

Principal Investigator

Jeffrey Weitzel

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beckman Research Institute

Authority:

United States: Food and Drug Administration

Study ID:

NCI-2011-01379

NCT ID:

NCT01149083

Start Date:

June 2010

Completion Date:

Related Keywords:

  • brca1 Mutation Carrier
  • brca2 Mutation Carrier
  • Recurrent Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer
  • Breast Neoplasms

Name

Location
Memorial Sloan Kettering Cancer Center New York, New York  10021
Mayo Clinic Rochester, Minnesota  55905
Washington University School of Medicine Saint Louis, Missouri  63110
Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Massachusetts General Hospital Cancer Center Boston, Massachusetts  02114
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Weill Medical College of Cornell University New York, New York  10021
University of Colorado Denver, Colorado  80217
City of Hope Medical Center Duarte, California  91010
Mayo Clinic in Arizona Scottsdale, Arizona  85259-5404
Mayo Clinic in Florida Jacksonville, Florida  32224
University of Pittsburgh Pittsburgh, Pennsylvania  15261
UC Davis Comprehensive Cancer Center Sacramento, California  95817
University of Chicago Comprehensive Cancer Center Chicago, Illinois  60637-1470
M D Anderson Cancer Center Houston, Texas  77030
University of Southern California Los Angeles, California  90033
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania  17033
Magee-Womens Hospital - University of Pittsburgh Medical Center Pittsburgh, Pennsylvania  15213